Show simple item record

dc.contributor.authorAdamo, Luigi
dc.contributor.authorStaloch, Lora J
dc.contributor.authorRocha-Resende, Cibele
dc.contributor.authorMatkovich, Scot J
dc.contributor.authorJiang, Wenlong
dc.contributor.authorBajpai, Geetika
dc.contributor.authorWeinheimer, Carla J
dc.contributor.authorKovacs, Attila
dc.contributor.authorSchilling, Joel D
dc.contributor.authorBarger, Philip M
dc.contributor.authorBhattacharya, Deepta
dc.contributor.authorMann, Douglas L
dc.date.accessioned2019-11-20T19:42:29Z
dc.date.available2019-11-20T19:42:29Z
dc.date.issued2018-06-07
dc.identifier.citationJCI Insight. 2018;3(11):e120137. https://doi.org/10.1172/jci.insight.120137.en_US
dc.identifier.issn2379-3708
dc.identifier.pmid29875326
dc.identifier.doi10.1172/jci.insight.120137
dc.identifier.urihttp://hdl.handle.net/10150/636218
dc.description.abstractDespite the long-standing recognition that the immune response to acute myocardial injury contributes to adverse left ventricular (LV) remodeling, it has not been possible to effectively target this clinically. Using 2 different in vivo models of acute myocardial injury, we show that pirfenidone confers beneficial effects in the murine heart through an unexpected mechanism that depends on cardiac B lymphocytes. Naive hearts contained a large population of CD19+CD11b–CD23–CD21–IgD+IgMlo lymphocytes, and 2 smaller populations of CD19+CD11b+ B1a and B1b cells. In response to tissue injury, there was an increase in neutrophils, monocytes, macrophages, as well as an increase in CD19+ CD11b– B lymphocytes. Treatment with pirfenidone had no effect on the number of neutrophils, monocytes, or macrophages, but decreased CD19+CD11b– lymphocytes. B cell depletion abrogated the beneficial effects of pirfenidone. In vitro studies demonstrated that stimulation with lipopolysaccharide and extracts from necrotic cells activated CD19+ lymphocytes through a TIRAP-dependent pathway. Treatment with pirfenidone attenuated this activation of B cells. These findings reveal a previously unappreciated complexity of myocardial B lymphocytes within the inflammatory infiltrate triggered by cardiac injury and suggest that pirfenidone exerts beneficial effects in the heart through a unique mechanism that involves modulation of cardiac B lymphocytes.en_US
dc.description.sponsorshipNIH [R01HL107594-06, T32 HL007081]en_US
dc.language.isoenen_US
dc.publisherAMER SOC CLINICAL INVESTIGATION INCen_US
dc.rightsCopyright © 2018, American Society for Clinical Investigationen_US
dc.subjectB cellsen_US
dc.subjectCardiologyen_US
dc.subjectHeart failureen_US
dc.titleModulation of subsets of cardiac B lymphocytes improves cardiac function after acute injuryen_US
dc.typeArticleen_US
dc.contributor.departmentUniv Arizona, Dept Immunobiolen_US
dc.identifier.journalJCI INSIGHTen_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleJCI insight
refterms.dateFOA2019-11-20T19:42:30Z


Files in this item

Thumbnail
Name:
120137.1-20190423131554-covere ...
Size:
1.603Mb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record